2016 was a mixed year for Lupin. It completed the acquisition of U.S.-based Gavis in March 2016, obtaining its first manufacturing site in the U.S., along with some 60 ANDA filings pending approval with the FDA at that time. But a Form 483 for its Goa plant and two large-scale drug recalls because of failed ingredients were setbacks.
